Immune thrombocytopenia (ITP), previously called idiopathic thrombocytopenic purpura, is a rare blood disorder where your body’s immune system attacks and destroys your platelets. Platelets help form ...

Sutimlimab demonstrated rapid efficacy in the study cohort, and platelet level improvements were sustained for the duration of treatment in nearly half of the participants. Preventing and resolving ...

Findings showed 23% of patients treated with rilzabrutinib achieved durable platelet response compared with none of the patients receiving placebo. The Food and Drug Administration (FDA) has approved ...

Sept. 27, 2004 — Successful eradication of Helicobacter pylori infection results in significant platelet recovery in 56% of patients with chronic idiopathic thrombocytopenic purpura (ITP), according ...

Purpose: The pharmacology, pharmacokinetics, dosage and administration, efficacy, safety, effects on quality of life, and place in therapy of romiplostim are reviewed. Summary: Romiplostim is a second ...

The FDA also approved Doptelet Sprinkle oral granules for use in children aged 1 to less than 6 years. The Food and Drug Administration (FDA) has approved Doptelet ® (avatrombopag) for the treatment ...

The U.S. Food and Drug Administration today approved Promacta (eltrombopag) to treat low blood platelet count in pediatric patients – ages one year and older – with a rare blood disorder called ...

Results of a phase 3 study presented Sunday found efgartigimod allowed a third of patients with immune thrombocytopenia (ITP) to quickly achieve platelet levels that signal an ability to avoid sudden ...

There are no widely available therapies approved for this indication ...

Doptelet (avatrombopag) is used to increase platelet count in certain situations. The typical dosage is 1 to 3 oral tablets taken once daily. Your specific dosage depends on factors such as your ...